Search results
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 1 day agoPrevnar sales inched 2% ahead to $6.44 billion. But other key products saw downfalls. Revenue from...
Hussman Strategic Advisors Inc. Reduces Stock Holdings in Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 4 days agoHussman Strategic Advisors Inc. lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 60.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned ...
Desjardins Global Asset Management Inc. Has $115,000 Holdings in Biogen Inc. (NASDAQ:BIIB)
ETF DAILY NEWS· 6 days agoDesjardins Global Asset Management Inc. cut its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 86.0% in the 4th quarter, according to its most recent Form 13F filing with the ...
Biogen (NASDAQ:BIIB) Receives Buy Rating from Needham & Company LLC
ETF DAILY NEWS· 22 hours agoNeedham & Company LLC reissued their buy rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a report published on Wednesday morning, Benzinga reports. The brokerage currently has a $294.00 ...
Greenleaf Trust Increases Position in Biogen Inc. (NASDAQ:BIIB)
ETF DAILY NEWS· 3 days agoGreenleaf Trust increased its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 20.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission ...
Biogen (BIIB) Scheduled to Post Quarterly Earnings on Wednesday
ETF DAILY NEWS· 4 days agoBiogen (NASDAQ:BIIB – Get Free Report) will be announcing its earnings results before the market opens on Wednesday, April 24th. Analysts expect the company to announce earnings of $3.48 per ...
Oppenheimer Lowers Biogen (NASDAQ:BIIB) Price Target to $270.00
ETF DAILY NEWS· 5 days agoBiogen (NASDAQ:BIIB – Get Free Report) had its price objective dropped by equities researchers at Oppenheimer from $290.00 to $270.00 in a research note issued on Friday, Benzinga reports. The ...